Tubulis generates uniquely matched antibody-drug conjugates (ADCs) with superior biophysical properties, demonstrating durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. Their lead programs, TUB-040 and TUB-030, are being evaluated in the clinic for high-need solid tumor indications. Tubulis aims to expand the therapeutic potential of ADCs for patients, partners, and through their pipeline.